Dendreon Takes $400M Valeant Bid, Nixes Ch. 11 Auction
Valeant Pharmaceuticals International Inc. emerged victorious Tuesday in a bidding war for Dendreon Corp. when a deadline expired for other suitors of the bankrupt prostate-cancer treatment developer to challenge a sweetened,...To view the full article, register now.
Already a subscriber? Click here to view full article